ESC Premium Access

Will the availability of specific reversal agents change the use of NOACs?

Congress Session

About the speaker

Professor Freek Verheugt

Onze Lieve Vrouwe Gasthuis, Amsterdam (Netherlands (The))
21 presentations
0 follower

3 more presentations in this session

When should I use reversal agents for NOACs?

Speaker: Professor G. Lip (Liverpool, GB)


Reversal of the thrombin inhibitor dabigatran.

Speaker: Associate Professor A. Niessner (Vienna, AT)


Reversal of FXa inhibitors.

Speaker: Associate Professor S. Wassmann (Munich, DE)


Access the full session

Reversal of NOACs' effect: when and how?

Speakers: Professor F. Verheugt, Professor G. Lip, Associate Professor A. Niessner, Associate Professor S. Wassmann

About the event



27 August - 31 August 2016

Sessions Presentations

Related content

Open Access

Welcome and introduction.

21 May 2022

EHRA Premium Access

Effectiveness and safety of edoxaban in 27,333 patients from ETNA-AF with and without a history of intracranial haemorrhage after 2 years of treatment

4 April 2022

ESC Premium Access

Comparative effectiveness and safety of edoxaban vs warfarin in patients with atrial fibrillation: a nationwide cohort study

28 August 2021

This platform is supported by

logo Novo Nordisk